Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity

NCT01844232 is registered in ClinicalTrials.gov with RVL Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01844232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01844232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Lead sponsor
RVL Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2013
Completion date
January 31, 2015
Enrollment
150 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, spasticity